



# Optimization and Repeatability of Multipool Chemical Exchange Saturation Transfer MRI of the Prostate at 3.0 T

Vincent Stephen Evans, MPhys,<sup>1\*</sup> Francisco Torrealdea, PhD,<sup>1</sup> Marilena Rega, PhD,<sup>2</sup> Mrishtha Brizmohun Appayya, MD,<sup>1</sup> Arash Latifoltojar, MD,<sup>1</sup> Harbir Sidhu, MD, FRCR,<sup>1,3</sup> Mina Kim, PhD,<sup>4</sup> Aaron Kujawa, MS,<sup>4</sup> Shonit Punwani, PhD, FRCR,<sup>1</sup> Xavier Golay, PhD,<sup>4</sup> and David Atkinson, PhD<sup>1</sup>

**Background:** Chemical exchange saturation transfer (CEST) can potentially support cancer imaging with metabolically derived information. Multiparametric prostate MRI has improved diagnosis but may benefit from additional information to reduce the need for biopsies.

**Purpose:** To optimize an acquisition and postprocessing protocol for 3.0 T multipool CEST analysis of prostate data and evaluate the repeatability of the technique.

**Study Type:** Prospective.

**Subjects:** Five healthy volunteers (age range: 24–47 years; median age: 28 years) underwent two sessions (interval range: 7–27 days; median interval: 20 days) and two biopsy-proven prostate cancer patients were evaluated once. Patient 1 (71 years) had a Gleason 3 + 4 transition zone (TZ) tumor and patient 2 (55 years) had a Gleason 4 + 3 peripheral zone (PZ) tumor.

**Field Strength:** 3.0 T. Sequences run: T<sub>2</sub>-weighted turbo-spin-echo (TSE); diffusion-weighted imaging; CEST; WASABI (for B<sub>0</sub> determination).

**Assessment:** Saturation, readout, and fit-model parameters were optimized to maximize in vivo amide and nuclear Overhauser effect (NOE) signals. Repeatability (intrasession and intersession) was evaluated in healthy volunteers. Subsequently, preliminary evaluation of signal differences was made in patients. Regions of interest were drawn by two post-FRCR board-certified readers, both with over 5 years of experience in multiparametric prostate MRI.

**Statistical Tests:** Repeatability was assessed using Bland–Altman analysis, coefficient of variation (CV), and 95% limits of agreement (LOA). Statistical significance of CEST contrast was calculated using a nonparametric Mann–Whitney *U*-test.

**Results:** The optimized saturation scheme was found to be 60 sinc-Gaussian pulses with 40 msec pulse duration, at 50% duty-cycle with continuous-wave pulse equivalent B1 power (B1<sub>CWPE</sub>) of 0.92 μT. The magnetization transfer (MT) contribution to the fit-model was centered at –1.27 ppm. Intersession coefficients of variation (CVs) of the amide, NOE, and magnetization transfer (MT) and asymmetric magnetization transfer ratio (MTR<sub>asym</sub>) signals of 25%, 23%, 18%, and 200%, respectively, were observed. Fit-metric and MTR<sub>asym</sub> CVs agreed between readers to within 4 and 10 percentage points, respectively.

**Data Conclusion:** Signal differences of 0.03–0.10 (17–43%) detectable depending upon pool, with MT the most repeatable (signal difference of 17–22% detectable).

**Level of Evidence:** 2

**Technical Efficacy:** Stage 2

J. MAGN. RESON. IMAGING 2019.

CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) imaging allows for the detection of in vivo metabolites via the continual exchange of labile protons with water. The technique has been applied in cancer imaging at clinical field strengths across a range of anatomical regions including brain,<sup>1,2</sup> breast,<sup>3–5</sup> head and neck,<sup>6,7</sup> and

View this article online at [wileyonlinelibrary.com](http://wileyonlinelibrary.com). DOI: 10.1002/jmri.26690

Received Nov 5, 2018, Accepted for publication Feb 6, 2019.

\*Address reprint requests to: V.E., Centre for Medical Imaging, University College London, 43-45 Foley St, Fitzrovia, London, W1W 7TS, UK. E-mail: [vincent.stephen.evans@gmail.com](mailto:vincent.stephen.evans@gmail.com)

From the <sup>1</sup>Centre for Medical Imaging, University College London, London, UK; <sup>2</sup>Institute of Nuclear Medicine, University College London Hospital NHS Foundation Trust, University College Hospital, London, UK; <sup>3</sup>Radiology Department, University College London Hospital NHS Foundation Trust, University College Hospital, London, UK; and <sup>4</sup>Institute of Neurology, University College London, London, UK

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

prostate<sup>8,9</sup> with sequences performed in clinically feasible scan times.

A key diagnostic tool in prostate cancer detection and treatment pipeline is the use of multiparametric magnetic resonance imaging (mp-MRI) protocols and radiologist scoring schemas, which are becoming increasingly harmonized across sites as radiological consensus continues to emerge.<sup>10,11</sup>

While mp-MRI has been shown to improve detection of clinically significant prostate cancer<sup>12</sup> approximately a third of cases remain equivocal.<sup>13,14</sup> In these cases, there would be a clear clinical benefit if additional information could be provided by imaging to support diagnosis and reduce the need for biopsies.

CEST imaging is sensitive to changes in the concentrations and the pH environment of exchangeable protons found in metabolites such as lactate, citrate, and other mobile proteins and peptides that exhibit altered behavior as part of metabolomic changes that occur in prostate cancer.<sup>15</sup> Jia et al<sup>8</sup> demonstrated that amide proton transfer ratio (APTR) measurements in regions of prostate cancer were significantly higher than in benign peripheral zone (PZ) regions, while Takayama et al<sup>9</sup> analyzed CEST data from 66 prostate tumors that suggested that amide proton transfer (APT) measurements of Gleason 7 lesions are higher than for Gleason 6, 8, and 9 lesions and for noncancerous PZ tissue. Lorentzian fitting of CEST z-spectra gives the ability to derive information from several different exchange effects that would otherwise be convolved into a single asymmetry measurement and, to the best of our knowledge, has not previously been explored in the prostate at 3.0 T.

In order for the clinical potential of the technique to be explored fully, an optimization of the acquisition and analysis, and evaluation of the repeatability of the results, is needed.

The present work has two primary objectives. The first is to optimize an acquisition and postprocessing protocol suitable for z-spectrum fitting analysis of prostate data acquired at 3.0 T with clinically feasible scan times. The second is to evaluate the intra- and intersession repeatability of both the fitting and asymmetry metrics derived from the optimized protocol. It is hypothesized that the repeatability scores of the CEST fitting metrics will outperform those from asymmetry analysis.

## Materials and Methods

### Subjects

The recruitment of healthy volunteers and patients was approved by the local Institutional Ethics Board. Written informed consent was obtained prior to all examinations.

Five healthy male volunteers (age range 24–47 years; median age: 28 years) were recruited. Two of these volunteers were initially scanned as part of the sequence and postprocessing optimization steps described below. All five healthy volunteers then attended two separate scanning sessions (range of interscan intervals: 7–27 days;

median interval: 20 days) where data for the repeatability analysis was collected.

Patients were identified by a radiologist with 10 years of experience (coauthor S.P.) during local multidisciplinary team meetings. Two patients with transrectal ultrasound (TRUS) biopsy-proven tumors, both of whom were under active surveillance for lesions scoring 5/5 on PI-RADS, with maximum lesion size >10 mm and whose biopsies had taken place over 4 months prior to recruitment were recruited and made a single attendance. Patient 1 (age 71) had a right-sided Gleason 3 + 4 TZ tumor with prostate-specific antigen (PSA) concentration of 8.4 ng/ml and patient 2 (age 55) had a right-sided Gleason 4 + 3 PZ tumor with PSA concentration of 6.2 ng/ml. PSA measurements were made 2 months prior to the research scans.

### MRI Protocol

Data were acquired with a 3.0 T Achieva MRI scanner (Philips Healthcare, Best, The Netherlands) using a 32-channel cardiac coil. All volunteer and patient scans were performed axially in the feet-first position. A T<sub>2</sub>-weighted (T<sub>2</sub>w) whole-volume turbo-spin-echo (TSE) acquisition and, in patients, a diffusion-weighted imaging (DWI) acquisition was performed at the start of the session. These were then used to plan the CEST scan. In patients, both of which had known and previously classified tumors, prior mp-MRI was also available to support the radiologists when planning. In healthy volunteers, a single-slice was positioned at the largest axial cross-section of the prostate. In patients, the slice was positioned at the largest axial cross-section of the tumor as determined by radiology research fellows (A.L. and H.S.) with access to prior clinical imaging. The shim voxel was aligned with the imaging plane.

The T<sub>2</sub>w scan was an axial multishot TSE (TSE factor = 16). Echo time (TE) = 100 msec, repetition time (TR) = 4000 msec, field-of-view (FOV) = 180 × 180 mm<sup>2</sup>, resolution = 224 × 218 with 30, 3-mm thick slices. Refocusing control and fat suppression were off. A parallel imaging acceleration (SENSE) factor of 1.3 (RL) was used. The number of signal averages (NSA) was 1. Scan duration was 3 minutes 27 seconds.

The DWI scan used an axial multislice Cartesian single-shot echo planar imaging (EPI) readout. TE = 79 msec, TR = 2360 msec, FOV = 220 × 220 mm<sup>2</sup>, resolution = 168 × 168 with 14, 5-mm slices. NSA = 6. Images were acquired using a single b-factor of 2000. Spectral presaturation with inversion recovery (SPIR) fat suppression was applied. Scan duration was 2 minutes 10 seconds.

The CEST scan readout was an axial single-shot TSE readout. TE = 14 msec, TR = 5100 msec, FOV = 140 × 140 mm<sup>2</sup>, resolution = 64 × 63 with a single slice thickness 4 mm. Refocusing control was set to 120° and SPIR fat suppression was applied. No parallel imaging acceleration was used. NSA = 1. The scan duration was 5 minutes 42 seconds.

### Offset Sampling Frequencies

Saturated images were acquired with 0.25 ppm spacing between ±5 ppm, with additional measurements at ±5.5, ±6.0, ±6.5, ±7.0, ±7.5, ±10.0, ±15.0, ±20.0, ±25.0, ±30.0, ±100.0, and ±300.0 ppm allowing for sampling of the broad semisolid MT contribution. An unsaturated reference image was acquired for z-spectrum normalization.

## WASABI

$B_0$  maps were acquired using a WASABI (water shift and  $B_1$ ) sequence that was adapted from parameters outlined in the literature.<sup>16</sup> Data were acquired at 20 saturation frequency offsets, evenly spaced between  $\pm 3$  ppm. A 5-msec block saturation pulse of flip angle  $284^\circ$  ( $B_{1CWPE} = 3.7 \mu\text{T}$ ) was applied before each readout. The readout parameters and slice-planning were the same as for the CEST scan. The duration of each WASABI scan was 41 seconds.

## Data Analysis

Data processing was performed using in-house developed software written using MatLab (MathWorks, Natick, MA, R2016a).

$B_0$  inhomogeneity corrections were carried out by interpolating the CEST z-spectra to 1 Hz (0.008 ppm) frequency intervals and shifting the spectra on a voxel-by-voxel basis using  $B_0$  maps generated using WASABI data.

**LORENTZIAN FITTING.** The direct saturation (DS), CEST, and nuclear Overhauser effect (NOE)<sup>17–19</sup> pools were modeled using Lorentzian lineshapes,<sup>20–22</sup> described as a function of the saturation frequency,  $\omega$  by:

$$L_i(\omega, \omega_{0i}, \Gamma_i, A_i) = A_i \frac{\Gamma_i}{2\pi(\omega - \omega_{0i})^2 + (0.5\Gamma_i)^2} \quad (1)$$

Where  $\omega_{0i}$  is the offset frequency of pool  $i$ ,  $\Gamma_i$  is the full-width-half-maximum (FWHM), and  $A_i$  is a scaling factor.

The CEST effects were jointly modeled using a single Lorentzian to mitigate the risks of overfitting. This Lorentzian was centered at the APT frequency offset of 3.5 ppm and is henceforth referred to as the amide pool. Similarly, a single Lorentzian, located at  $-3.5$  ppm, was used to account for the NOE effect.<sup>22,23</sup>

The MT contribution to the z-spectrum was modeled using a super-Lorentzian curve,<sup>21,24,25</sup> which is described by:

$$SL(\omega, \omega_{0SL}, T_2^b, A_{SL}) = A_{SL} \int_0^{\frac{\pi}{2}} d\theta \sin\theta \sqrt{\frac{2}{\pi} \frac{T_2^b}{|3\cos^2\theta - 1|}} e^{-2\left(\frac{(\omega - \omega_{0SL})T_2^b}{|3\cos^2\theta - 1|}\right)^2} \quad (2)$$

where  $T_2^b$  is the  $T_2$  of the MT pool,  $\omega_{0SL}$  is the central offset frequency of the lineshape relative to water, and  $A_{SL}$  is a scaling factor.

The offset frequency of the MT contribution to the z-spectrum has been seen to vary across tissues.<sup>23,26,27</sup> This issue is discussed by van Zijl et al<sup>28</sup> and Hua et al<sup>26</sup> and is likely due to a combination of causes including differences in the constituents of the macromolecular pool across tissues, which is thought to contain both slow- and fast-exchanging contributors. The MT offset frequency was estimated by fitting the z-spectra from many voxels using only data points outside of the  $\pm 15$  ppm range, where CEST and NOE

contributions are negligible. The median offset from this analysis was used for all subsequent fits and the super-Lorentzian lineshape was symmetrically interpolated between  $\pm 20$  ppm using a cubic-spline to remove the pole that occurs close to its central frequency.

A whole-fit frequency offset term,  $h$ , was included in the fit equation to account for imperfect  $B_0$ -field inhomogeneity corrections and a vertical constant signal term  $v$  was also included to account for the effects of noise during z-spectrum normalization. After fitting, both the normalized data points and the amplitude parameters extracted from the fit were renormalized using the fitted vertical offset value (using a voxelwise multiplication by  $1/(1-v)$ ). This ensured that the data and fit results were properly normalized.

The general overall fit equation for a renormalized z-spectrum with contributions from  $n$  pools (including DS, CEST, and NOE effects) and an MT pool is given by:

$$M_z(\omega) = 1 - \sum_{i=1}^n L_i(\omega - h, \omega_{0i}, \Gamma_i, A_i) - SL(\omega - h, \omega_{0SL}, T_2^b, A_{SL}) \quad (3)$$

Fitting analyses were performed using a nonlinear least squares algorithm and the fit expression described in Eq. 3 customized for a four-pool model (DS, amide, NOE, MT), with all data points weighted equally. The primary output metrics of interest from the fitting were taken to be the heights of the amide, NOE, and MT peaks.

**ASYMMETRY ANALYSIS.** The asymmetric magnetization transfer ratio ( $MTR_{\text{asym}}$ ) at offset frequency  $\omega$  is calculated by the expression  $MTR_{\text{asym}}(\omega) = \frac{M_z(-\omega) - M_z(\omega)}{\omega_0}$ . For this analysis, the  $MTR_{\text{asym}}$  was calculated at  $\omega = 3.5$  ppm as per previous prostate APT work.<sup>8,9</sup>

## Saturation Scheme and TR Optimization

A pulsed-saturation scheme was used, comprised of a train of sinc-Gaussian shaped pulses with parameters: pulse duration ( $\tau_p$ ), interpulse-delay ( $\tau_d$ ), saturation flip angle ( $\theta$ ), and the number of pulses ( $N$ ). Z-spectra were acquired in a healthy volunteer using a range of values of  $N$  (20 to 60) to determine the number of pulses required to achieve saturation steady-state.

The saturation flip angle was subsequently optimized by acquiring data from a second healthy volunteer using a range of values of saturation flip angle  $\theta$  and selecting the flip angle that maximized the signal from the fitted amide and NOE pools obtained using the four-pool model described by equation 3.

A range of TR values between 2 and 6 seconds were explored by acquiring unsaturated images repeatedly in a healthy volunteer and comparing the total absolute signal observed in each case. These results were cross-referenced with values quoted in the literature for the  $T_1$  of the prostate at 3.0 T<sup>29</sup> and a selection was made to allow for >95% signal recovery between TSE readouts.

### Region of Interest Analysis

Regions of interest (ROIs) were drawn in a single-session by coauthor H.S., with 10 years of experience in prostate radiology, on unsaturated CEST reference scans from all healthy volunteer and patient scans. This was done with a graphical user interface (GUI) that was created using an in-house developed MatLab script. For healthy volunteers, ROIs were drawn in the right and left PZ, right and left TZ, and right and left obturator internus muscles. In patients, the same ROIs were drawn, however in the affected zone (TZ or PZ) one ROI was drawn in the tumor and one in apparently-uninvolved-tissue (AUT), ie, not necessarily contralaterally.

Readers had access to prior clinical mp-MRI reports and pathology results and the  $T_2w$  and DWI images acquired during this study. This was to ensure that the tumor was localized in the acquired images as accurately as possible by both readers to allow for subsequent evaluation of the signal differences between different regions.

A second reader (coauthor M.B.A.) with 5 years of experience in prostate radiology independently redrew the ROIs. Repeatability and tumor contrast analyses were performed using both sets of ROIs.

### Repeatability in Healthy Volunteers

The  $B_0$ -corrected z-spectra from all voxels within each ROI were averaged to generate a single z-spectrum per ROI that was fitted using the four-pool model to extract amide, NOE, and MT measurements, and the  $MTR_{asym}$  was calculated. Bland–Altman plots were used to evaluate the intrasession and intersession repeatability of the technique.<sup>30</sup> For intrasession repeatability, the results from the first scan of each session were compared with the results from the second scan of the same session, with scans being separated by a total of 6 minutes 23 seconds. For intersession repeatability, the results from the first scan of the first session were compared with the results of the first scan of the second session, and similarly with the second scan of each session. The coefficient of variation (CV) was calculated in the




FIGURE 1: Z-spectra from large ROIs drawn over the whole prostate when using saturation trains with  $N = 20, 30, 40, 50,$  and  $60$  Gaussian pulses. The error bars show the standard deviation of the signal across all voxels within each ROI. The z-spectrum approaches saturation steady-state with increasing  $N$ .

standard way for each metric (amide, NOE, MT, and  $MTR_{asym}$ ). The 95% limits of agreement (LOA), derived in each case from the Bland–Altman analysis, are the values within which 95% of the differences between measurements are expected to lie, and the bias is the mean difference between scans. In the ideal case of perfect repeatability with no noise, the LOA, bias, and CV are all zero.

### Contrast in Tumor Tissue

Maps of the amide, NOE, and MT peak-heights, and the  $MTR_{asym}$  were generated by performing voxel-wise analysis of the patient scans. Boxplots of the signal from all voxels within tumor and AUT ROIs were created. The significance of the observed image contrast between tumor and AUT in patient scans was evaluated by treating each group of voxels within an image as an independent sample and applying a nonparametric Mann–Whitney  $U$ -test with  $P < 0.05$  taken to be significant.

## Results

### Acquisition and Fitting Protocol Optimization

Figure 1 shows the z-spectra from an ROI drawn over the whole prostate for different numbers of saturation pulses,  $N$ . Saturation steady-state is approached with increasing  $N$  and differences between subsequent z-spectra became smaller with each increment of 10 pulses. The trade-off between small gains in saturation and increased scan time led to the selection of 60 pulses for the final saturation scheme. For the given saturation timings ( $\tau_p = \tau_d = 40$  msec) this corresponds to 4.8 seconds of total saturation time.

In keeping with reference values from the literature<sup>29</sup> and data that were acquired in a healthy volunteer (data not





FIGURE 2: Histogram showing the distribution of offset frequencies of the fitted MT super-Lorentzian across prostate voxels taken from five healthy volunteers when fitting only data points outside of the  $\pm 15$  ppm range.



**FIGURE 3:** A plot of the mean heights of the fitted amide, NOE, and MT peaks over all voxels of a whole prostate for a range of saturation flip angles. Error bars show the standard deviation over all voxels. The amide and NOE signals were both maximized using a flip angle of 1133°.

shown), a TR of 5 sec or above was found to allow for >95% signal recovery of  $M_z$  between readouts. The final TR was chosen to be 5.1 sec to accommodate the TSE readout (245 msec) and 4.8 sec of saturation.

Figure 2 shows the histogram distribution of super-Lorentzian offset frequencies when fitting only MT data points outside of the  $\pm 15$  ppm range. The median offset frequency was  $-1.27$  ppm with 25<sup>th</sup> and 75<sup>th</sup> percentiles at  $-2.04$  ppm and  $-0.04$  ppm, respectively. Based on these data,

the offset of the super-Lorentzian was fixed at  $-1.27$  ppm for all subsequent analysis. This is similar to values used in other Lorentzian fitting work.<sup>23</sup>

The heights of the fitted amide, NOE, and MT peaks as a function of saturation flip angle are shown in Fig. 3. The MT signal increased with increasing saturation power and the mean signals from the amide and NOE pools across the whole prostate were jointly maximized with a saturation flip angle of 1133°, corresponding to a  $B_{1CWPE}$  of 0.92  $\mu$ T. The fit parameters used in the final analysis are summarized in Table 1.

### Repeatability in Healthy Volunteers

Representative fitted z-spectra from ROIs drawn in the PZ, TZ, and obturator internus muscle of a single healthy volunteer are shown in Fig. 4.

Figure 5a–d show Bland–Altman plots for the intersession repeatability of the heights of the fitted amide, NOE, and MT lineshapes and the  $MTR_{asym}$  measurements, respectively, using the ROIs drawn by reader 1 (intrasession plots are not shown). The plots include the CV and the LOA expressed in units of  $M_0$ , which equates to  $M_z(\infty) = 1$  for a normalized z-spectrum.

The intrasession CVs of the amide, NOE, MT, and  $MTR_{asym}$  measurements in healthy volunteers using ROIs drawn by reader 1 were found to be 20%, 19%, 9.5%, and 150%, respectively. The corresponding intersession CVs were found to be 25%, 23%, 18%, and 200%, respectively.

**TABLE 1. Starting Values and Upper and Lower Bounds for All Parameters Used by the Z-spectrum Fitting Algorithm**

Z-spectrum contributor	Lineshape	Parameter	Starting value	Lower bound	Upper bound
Water	Lorentzian	$\omega_0$ (ppm)	0.0000	-0.0001	0.0001
		$\Gamma$ (ppm)	1.0	0.5	12.0
		$A$ (A.U)	0.8	0.1	1.0
Amide	Lorentzian	$\omega_0$ (ppm)	3.500	3.499	3.501
		$\Gamma$ (ppm)	2.0	0.5	12.0
		$A$ (A.U)	0.1	0.0	1.0
NOE	Lorentzian	$\omega_0$ (ppm)	-3.500	-3.501	-3.499
		$\Gamma$ (ppm)	2.0	0.5	12.0
		$A$ (A.U)	0.1	0.0	1.0
MT	Super-Lorentzian	$\omega_{0SL}$ (ppm)	-1.27000	-1.27001	-1.26999
		$T_2^b$ ( $\mu$ s)	10	1	50
		$A_{SL}$ (A.U)	0.500	0.001	1.000
Horizontal Offset (whole-fit)	Constant	$b$ (ppm)	0.0	-0.3	0.3
Vertical Offset (whole-fit)	Constant	$v$ (A.U)	0.0	-0.1	0.1

The full CV, LOA, and bias values for amide, NOE, MT, and  $MTR_{asym}$  measurements made using ROIs drawn by both readers are shown in Table 2 along with the intra-class correlation (ICC) coefficients between readers.

The LOA gives an indication of the threshold for reliable detectability of signal differences. Therefore, based on these data, we would expect to be able to reliably detect differences in the amplitudes of the fitted peaks from repeated scans within a single session of 0.04–0.05 (33–38% for amide and NOE and 17–22% for MT) or higher. The bias is close to zero in every case.

### Signal Differences in Patients

Maps of the amide, NOE, MT, and  $MTR_{asym}$  signal intensities from each patient are shown in Fig. 6 alongside the corresponding  $T_{2w}$  and DWI ( $b = 2000$ ) images. DWI is particularly useful for identifying regions of PZ tumor as seen in the figure. Tumor and AUT ROIs are overlaid onto the images, with tumor marked with a red arrow on the  $T_{2w}$  images.

Boxplots of the amide, NOE, and MT signal, and the  $MTR_{asym}$  values from all voxels in AUT and tumor ROIs are shown in Fig. 7 for both patients and both readers. Statistical significance of signal differences between regions were assessed using a nonparametric Mann–Whitney  $U$ -test with significance levels of  $P < 0.05$ ,  $P < 0.01$ , and  $P < 0.001$  denoted in the boxplots by \*, \*\*, and \*\*\*, respectively.

The median amide, NOE, MT, and  $MTR_{asym}$  signals in regions of tumor and AUT, the difference in median signals between these regions ( $\Delta$ ), and the corresponding significance values,  $P$ , are fully tabulated in Table 3. Measurements showing significant differences between tumor and AUT are highlighted in bold.

Visually, hypointensities of both the amide and NOE signals are observed in the region of TZ tumor when compared with apparently uninvolved TZ (patient 1), with corresponding hyperintensity of the MT signal.

For patient 2, the opposite contrast effect is observed, with hyperintensity of amide and NOE signals within the region of PZ tumor relative to apparently uninvolved PZ and a corresponding relative hypointensity of the MT signal. However, it should be noted in this case that the hyperintensities of amide and NOE signals within the tumor ROI appear to be part of broader structural features that are not localized to the tumor itself.

In the five volunteers, MT was the most repeatable parameter (see Table 2) with the lowest CV values and a threshold for signal detection of 0.04–0.05 (17–22%) or higher. In the PZ tumor patient, MT showed significant amplitude decreases for both scans and for both readers with signal changes in the range  $-0.039$  to  $-0.085$  (16–31%), consistent with the repeatability threshold.

## Discussion

In the current work, we optimized an acquisition and post-processing pipeline for multipool CEST imaging of the prostate at 3.0 T and evaluated the repeatability of the technique in healthy volunteers. We also subsequently applied it to two patients with proven prostate cancer.

CEST sequence parameters including number of pulses, saturation powers, and the TR were tuned to maximize the





FIGURE 4: Representative normalized z-spectra, fit results, and fit residuals from ROIs drawn in the PZ, TZ, and muscle in a single healthy volunteer, showing only the  $\pm 7$  ppm range. The four-pool fit results include contributions from water, amide, NOE, and MT. The  $MTR_{asym}$  has been scaled  $\times 5$  for improved visibility. The residual differences between the raw data and the fits are all less than 0.028.



**FIGURE 5:** Bland–Altman plots showing the intersession repeatability of the heights of the fitted (a) amide, (b) NOE, and (c) MT peaks, and (d) the  $MTR_{asym}$  measurements, using ROIs drawn by reader 1. Plots include the 95% LOA expressed in absolute terms and as a percentage, the bias, and the CV.

heights of the fitted CEST and NOE peaks and the offset frequency of the fitted MT peak was also estimated.

The combined scan time of the CEST and WASABI scans was clinically acceptable at 6 minutes 23 seconds. The pulse duration and interpulse delay parameters were not explored during the optimization, as prior experimentation on this scanner had indicated that saturation trains of longer than  $\sim 1$  sec were not possible when using duty cycles above 50% due to specific absorption rate (SAR) and hardware restrictions. A pulse duration of 40 msec was chosen because it gives rise to spectral selectivity approximating the frequency sampling that was used (0.25 ppm or 32 Hz in the central region of the z-spectrum).

As expected, the intrasession repeatability scores were found to be superior to the intersession repeatability scores in every case, as indicated by lower CV and LOA values.

Bland–Altman analysis showed that the CV values for all fit results (both intrasession and intersession) were 25% or lower. The intrasession 95% LOA for amide, NOE, and MT amplitude differences were found to be between 0.04–0.05 (17–38%). The corresponding intersession values for amide and NOE were between 0.04–0.06 (35–43%) and for MT this rose to 0.08–0.10 (33–38%). Therefore, the threshold

for detectable differences in fitted peak amplitudes in all cases ranged from 0.04–0.10 (17–43% depending on pool). While inspection of the LOA values between readers suggests reasonable interreader agreement, the ICC calculated for the intrasession variability between readers was particularly low, in part due to a low number of observations over a small range.

By comparison, a recent study of the repeatability of apparent diffusion coefficient (ADC) measurements in prostate mp-MRI at 3.0 T found limits of agreement ranging from 13.91% to 60.49% using an endorectal coil.<sup>31</sup> This puts the repeatability of CEST fitting metrics within the repeatability range of established ADC scans from the mp-MRI protocol.

The fitted MT peak was found to be the most repeatable measurement as quantified by CV and showed the most consistent change across both scans and readers in the PZ tumor patient.

This is perhaps not surprising, as it is the broadest contribution to the z-spectrum and all other contributions sit nested within it in the  $\pm 5$  ppm range. Magnetization transfer imaging (MTI) traditionally involves acquiring unsaturated images and images saturated at an offset typically  $> 1$  kHz off-resonance.

Recent work by Arlinghaus et al<sup>32</sup> showed good repeatability of quantitative MT (qMT) imaging of the breast at 3.0 T and Barrett et al<sup>33</sup> demonstrated that MTI shows promise for prostate cancer detection at 3.0 T.

It was considered whether the fitting model was able to distinguish decreases in T<sub>2</sub> (causing broadening of the water peak) from increases in MT signal. If the distinction could not be made, we would expect to see an inverse correlation between the T<sub>2</sub>w signal and MT height across the prostate voxels. No such correlation was observed (data not shown), which allayed concerns that the model was unable to distinguish between these two effects. This is attributed to the fact that MT points acquired between ±5.5 and ± 300 ppm allowed for proper characterization of the broad MT resonance.

The interreader differences in CV measurements for the fitted pools (amide, NOE, MT) are all smaller than four percentage points, with ICC of >0.99 suggesting that interreader variability is not the main source of variation.

As hypothesized, there is a marked difference between the levels of repeatability found using the fitting method, which showed maximum intrasession and intersession CV values of 20% and 25%, respectively, and the repeatability of

the MTR<sub>asym</sub> measurements, which showed maximum intrasession CV of 150% and an intersession CV of 200%.

The CV values for MTR<sub>asym</sub> repeatability are poorer than for the fitting metrics. The LOA values for MTR<sub>asym</sub>, while larger than those reported in other endogenous CEST repeatability studies,<sup>4,6</sup> were similar to or slightly lower than those of the fitted amide and NOE peaks. Both of these values may be improved by using a sequence optimized for MTR<sub>asym</sub> imaging, but that lies outside the scope of this work, which is primarily focused on z-spectrum fitting.

All MTR<sub>asym</sub> calculations in this work were made using the single-offset approach described in previous prostate APT work.<sup>8,9</sup> As an alternative, the use of multiple offset frequency points in the MTR<sub>asym</sub> calculation may reduce the effects of noise, and therefore improve the repeatability. For illustration, the CV values were recalculated using the mean MTR<sub>asym</sub> values over three offset frequencies (3.25, 3.5, and 3.75 ppm) and the intrasession CV values from both readers were reduced to 110%, with the intersession CV values dropping to 170% and 160%. These changes are attributed to noise averaging, although the optimal choice of integration range and its physiological significance would require further optimization and consideration.

**TABLE 2. Coefficients Of Variation (CV), 95% Limits of Agreement (LOA) and Bias of the Intrasession and Intersession Bland–Altman Plots Generated for the Amide, Nuclear Overhauser Effect (NOE), Magnetization Transfer (MT), and Asymmetric Magnetization Transfer Ratio (MTR<sub>asym</sub>) Signals in Five Healthy Volunteers**

CEST Metric	Intrasession					
	CV		LOA		Bias	
	Reader 1	Reader 2	Reader 1	Reader 2	Reader 1	Reader 2
Amide	20%	20%	0.05	0.05	0.00	0.00
NOE	19%	18%	0.04	0.04	0.00	0.00
MT	9.5%	7.4%	0.05	0.04	0.00	0.00
MTR <sub>asym</sub>	150%	140%	0.04	0.03	0.00	0.00
ICC	0.997		0.539		—	
CEST Metric	Intersession					
	Reader 1	Reader 2	Reader 1	Reader 2	Reader 1	Reader 2
	Reader 1	Reader 2	Reader 1	Reader 2	Reader 1	Reader 2
Amide	25%	22%	0.06	0.05	0.00	-0.01
NOE	23%	19%	0.05	0.04	-0.01	0.00
MT	18%	15%	0.10	0.08	0.00	0.00
MTR <sub>asym</sub>	200%	200%	0.05	0.05	0.00	0.00
ICC	0.999		0.835		—	

Results are shown for analysis done using regions of interest drawn by two separate readers. The intraclass correlation (ICC) coefficients are also provided.







FIGURE 6: Voxelwise maps of the heights of the fitted amide, NOE and MT peaks, and the  $MTR_{\text{asym}}$  measurements for (a–f) patient 1 with a TZ tumor and (g–l) patient 2 with a PZ tumor. The tumor and AUT ROIs are highlighted in red and blue, respectively, and the tumors are highlighted with a red arrow on the  $T_2w$  images. Visually, slight hypointensities are observed in the amide and NOE signal in the region of TZ tumor with corresponding hyperintensity in the MT signal and no significant change in the  $MTR_{\text{asym}}$ . Conversely, hyperintensities in the amide and NOE signals and hypointensities in both the MT and  $MTR_{\text{asym}}$  signals are observed in the region of PZ tumor, although the hyperintense amide and NOE signals are not localized only to the region of tumor.

Our results suggest that, when using the acquisition protocol outlined in this work, the fit-model described produces more repeatable CEST measurements than  $MTR_{\text{asym}}$  analysis. This is attributed to a reduction in the influence of noise when using whole z-spectrum fitting methods.

In the patient data the signal differences were most pronounced and showed the best agreement between readers for the second scan of the PZ tumor patient. In this case the amide, NOE, and  $MTR_{\text{asym}}$  signals all showed significant increases in the region of tumor, and the MT signal was significantly reduced. While not all of these signal differences were larger than the previously measured LOAs for respective pools, the statistical significance was evaluated between

groups of voxels drawn from within individual images and therefore relate to image contrast from a single subject and timepoint, not absolute signal measurements across multiple subjects and multiple timepoints. The results of the statistical significance tests should be interpreted in these terms.

The  $MTR_{\text{asym}}$  measurements are lower than those reported by Takayama et al.,<sup>9</sup> who observed  $MTR_{\text{asym}}$  values in the approximate range of 0.5–6% in PZ tissue and 3–8% in Gleason 7 tissue using a higher saturation power of 2.0  $\mu\text{T}$ . However, the  $MTR_{\text{asym}}$  signal enhancement in the PZ tumor (found to be  $\sim 3\%$  of  $M_0$ , averaged over readers and scans), was broadly consistent in magnitude with the signal changes observed by Takayama et al.<sup>9</sup> The magnitude of the



**FIGURE 7:** Boxplots showing the fitted amide, NOE, and MT peak heights and  $MTR_{asym}$  measurements from all voxels within tumor and AUT ROIs drawn by reader 1 for (a) both scans of patient 1 with a TZ tumor, (b) both scans of patient 2 with a PZ tumor. The red line indicates the median value of all voxels within the ROI, with the bottom and top edges of the blue box indicating the 25<sup>th</sup> and 75<sup>th</sup> percentiles, respectively. The whiskers extend to the most extreme data points not considered outliers. Data points that were more than 1.5 $\times$  the interquartile range away from the top or bottom of the box were classed as outliers and are plotted individually using red crosses. Significant signal differences between tumor and AUT within a given scan (as calculated using the Mann-Whitney *U*-test) are denoted using single, double, or triple asterisks representing  $P < 0.05$ ,  $P < 0.01$ , and  $P < 0.001$ , respectively.

significant signal differences between AUT and both tumor types were found to be in the range 0.01–0.06, which is consistent with the magnitude of changes expected based on previous studies.<sup>8,9</sup>

In terms of diagnostic prostate imaging, a comparison can be drawn between CEST and magnetic resonance spectroscopy (MRS), which are sources of alternative but complementary metabolic information. CEST provides chemically- and pH-weighted information derived from exchangeable protons across many metabolites, while MRS provides metabolite-specific profiling,<sup>6</sup> often focusing on the ratio of choline to citrate.<sup>6</sup> While MRS has already been discussed in the context

of mp-MRI,<sup>10</sup> CEST is an imaging technique capable of providing higher spatial resolution than MRS in comparable scan times (the CEST voxel size for this work is 2.2 mm<sup>2</sup> compared with 6.9 mm<sup>2</sup><sup>23,4</sup> and 5.9 mm<sup>2</sup><sup>26</sup> in two studies on prostate MRS). MRS is well-suited to the characterization of known lesions or tumors under active surveillance, but the higher in-plane resolution of CEST is an advantage when screening for unconfirmed lesions. CEST has already shown promise in cancer imaging,<sup>4,6,35</sup> and further investigation will allow for exploration of its potential utility.

There are several limitations of the study. No antispasmodic drug was given as part of this research and bowel

**TABLE 3. Median amide, NOE, MT, and MTR<sub>asym</sub> Signal Measurements in TZ AUT and TZ Tumor (Patient 1) and PZ AUT and PZ Tumor (Patient 2)**

Patient 1 (TZ tumor)								
Median signal	Scan 1							
	Reader 1				Reader 2			
	TZ AUT	TZ Tumor	$\Delta$	<i>P</i>	TZ AUT	TZ Tumor	$\Delta$	<i>P</i>
Amide	<b>0.113</b>	<b>0.102</b>	<b>-0.011 (-9.7%)</b>	<b>0.020</b>	<b>0.116</b>	<b>0.104</b>	<b>-0.012 (-10.3%)</b>	<b>0.042</b>
NOE	<b>0.109</b>	<b>0.096</b>	<b>-0.012 (-11.0%)</b>	<b>0.001</b>	<b>0.116</b>	<b>0.098</b>	<b>-0.018 (-15.5%)</b>	<b>0.016</b>
MT	<b>0.222</b>	<b>0.260</b>	<b>0.038 (17.1%)</b>	<b>&lt;0.001</b>	0.247	0.254	0.007 (2.8%)	0.357
MTR <sub>asym</sub>	0.018	0.019	<0.001 (0.0%)	0.928	<b>0.014</b>	<b>0.023</b>	<b>0.009 (64.3%)</b>	<b>0.017</b>
Patient 1 (TZ tumor) - Scan 2								
Median signal	Scan 2							
	Reader 1				Reader 2			
	TZ AUT	TZ Tumor	$\Delta$	<i>P</i>	TZ AUT	TZ Tumor	$\Delta$	<i>P</i>
Amide	<b>0.119</b>	<b>0.109</b>	<b>-0.010 (-8.4%)</b>	<b>&lt;0.001</b>	0.112	0.112	<0.001 (0.0%)	0.668
NOE	<b>0.120</b>	<b>0.102</b>	<b>-0.017 (-14.2%)</b>	<b>&lt;0.001</b>	0.114	0.104	-0.010 (-8.8%)	0.065
MT	<b>0.234</b>	<b>0.287</b>	<b>0.053 (22.7%)</b>	<b>&lt;0.001</b>	0.261	0.275	0.014 (5.4%)	0.342
MTR <sub>asym</sub>	0.009	0.007	-0.002 (-22.2%)	0.884	<b>0.007</b>	<b>0.015</b>	<b>0.008 (114.3%)</b>	<b>0.029</b>
Patient 2 (PZ tumor)								
Median signal	Scan 1							
	Reader 1				Reader 2			
	PZ AUT	PZ Tumor	$\Delta$	<i>P</i>	PZ AUT	PZ Tumor	$\Delta$	<i>P</i>
Amide	<b>0.131</b>	<b>0.148</b>	<b>0.017 (13.0%)</b>	<b>0.010</b>	0.142	0.140	-0.002 (-1.4%)	0.456
NOE	0.122	0.115	-0.008 (-6.6%)	0.334	0.122	0.123	<0.001 (0.00%)	0.898
MT	<b>0.227</b>	<b>0.172</b>	<b>-0.056 (-24.7%)</b>	<b>&lt;0.001</b>	<b>0.242</b>	<b>0.203</b>	<b>-0.039 (-16.1%)</b>	<b>&lt;0.001</b>
MTR <sub>asym</sub>	<b>0.020</b>	<b>0.065</b>	<b>0.045 (225%)</b>	<b>&lt;0.001</b>	<b>0.018</b>	<b>0.028</b>	<b>0.010 (55.6%)</b>	<b>0.042</b>
Median signal	Scan 2							
	Reader 1				Reader 2			
	PZ AUT	PZ Tumor	$\Delta$	<i>P</i>	PZ AUT	PZ Tumor	$\Delta$	<i>P</i>
Amide	<b>0.097</b>	<b>0.151</b>	<b>0.054 (55.7%)</b>	<b>&lt;0.001</b>	<b>0.091</b>	<b>0.127</b>	<b>0.036 (39.6%)</b>	<b>&lt;0.001</b>
NOE	<b>0.080</b>	<b>0.102</b>	<b>0.023 (28.8%)</b>	<b>0.004</b>	<b>0.075</b>	<b>0.100</b>	<b>0.025 (33.3%)</b>	<b>&lt;0.001</b>
MT	<b>0.233</b>	<b>0.171</b>	<b>-0.063 (-27.0%)</b>	<b>&lt;0.001</b>	<b>0.273</b>	<b>0.188</b>	<b>-0.085 (-31.1%)</b>	<b>&lt;0.001</b>
MTR <sub>asym</sub>	<b>0.014</b>	<b>0.050</b>	<b>0.035 (250%)</b>	<b>&lt;0.001</b>	<b>0.009</b>	<b>0.038</b>	<b>0.030 (333.3%)</b>	<b>&lt;0.001</b>

Data are shown for both scans of both patients using ROIs drawn by both readers. The signal difference,  $\Delta$ , is expressed both as an absolute value and also as a percentage of the AUT signal. All associated *P*-values were calculated using the Mann–Whitney *U*-test and are included. Significant differences in signal between tumor and AUT are highlighted in bold. Differences in repeated signal difference measurements ( $\Delta$ ) between scans and readers are broadly in line with the LOA values calculated earlier. The most consistent signal differences are found in the MT pool, where signal in tumor often varies by over 0.04, thereby exceeding the best-case intrasession LOA for MT. The second scan of patient 2 shows the largest overall signal differences and consistency between readers where both the amide and MT signal changes in PZ tumor are greater than the LOA for these two pools.

motion may affect the results. Motion correction of CEST data can be difficult due to changes in image contrast between saturation frequencies; however, methods currently being developed to address this could be applied in future work.<sup>36</sup>

To prevent overfitting, the number of free parameters cannot be too high. For this reason, in this work we used a four-pool model with a single CEST pool and a single NOE pool. Optimization of the offset frequencies of these two pools

was attempted by fitting many voxels with relaxed constraints on the upper and lower bounds of the offset frequencies, but the analysis did not converge (data not shown). We believe this to be due to the use of a reduced number of pools, the broadness of CEST resonances at 3.0 T, and the fact that different subregions of the prostate may have different CEST pool offsets. In response to this, reference values were used for the CEST and NOE offset frequencies.<sup>22,23</sup> In particular the amide resonant frequency of 3.5 ppm was selected because at the low B1 saturation powers we used, the saturation efficiency for the slow-exchanging amides is higher than for amine and hydroxyl groups. Future CEST studies at field strengths above 3.0 T may better characterize z-spectrum features in the prostate that will inform future fitting models. Generalization of these models across sites will require the consolidation of in-house postprocessing scripts after sufficient technical development and validation has taken place.

The horizontal offset term varied smoothly across the images and values were largely contained within the  $-0.02$  ppm to  $0.04$  ppm range (data not shown), suggesting that fitting artifacts in the prostate due to poor  $B_0$  correction are not a major concern when performing z-spectrum fitting with a horizontal offset. For this reason, regularization of the horizontal offset constant (for example, using IDEAL-fitting as per Zhou et al<sup>37</sup>) was not applied, although this could be applied in future work. Variation of the vertical offset parameter across the prostate (with values largely confined to within a range of  $\pm 0.01$ , data not shown) was not smoothly varying across the field of view, but as this term is included to correct for noise, this was expected.

A single-slice readout was chosen for the benefit of having a shorter readout time and the slice thickness was 4 mm. Partial volume effects may have influenced the results, although the slice positioning was centered at the largest cross-section of the gland in healthy volunteers, and across the largest cross-section of the tumors (which were both  $>10$  mm in diameter) in patients. It is expected that this will have helped to minimize partial volume effects in this study. As a clinical tool, the protocol would benefit from an increased number of slices with thickness  $<4$  mm to provide greater coverage and minimize these effects.

Optimization of saturation parameters for maximal absolute amide and NOE signals was performed in healthy volunteers using data from the whole prostate, including PZ and TZ subregions. The chosen saturation power of  $0.92 \mu\text{T}$  was broadly consistent with saturation powers used in other endogenous CEST studies utilizing z-spectrum fitting that utilize  $B1_{\text{CWPE}}$  in the region of  $1.0 \mu\text{T}$ .<sup>23,37</sup> For optimal cancer detection, a protocol needs to provide an adequate level of signal and contrast between AUT and tumor and variations in  $T_1$  and  $T_2$  values, pH and metabolite concentrations between regions may influence the optimal parameter set. Further work using patients may refine the protocol for cancer detection.

Multipool CEST imaging protocols similar to the one outlined in this work may be able to integrate traditional MTI metrics with semiquantitative CEST measurements to provide more detailed exchange-based parametric information in support of mp-MRI protocols for the imaging of prostate cancer.

The accuracy of repeatability scores and evaluation of CEST contrast in prostate tumors would be improved with the inclusion of more subjects, but the numbers included in this study provide a benchmark for repeatability and CEST contrast in tumors similar to previous works<sup>6,9</sup> and these initial results may be used to power future prostate CEST studies.

In summary, we optimized a full-z-spectrum acquisition and fitting protocol suitable for prostate imaging on a 3.0 T scanner within clinically feasible scan times. The repeatability of the fitting metrics are comparable to other mp-MRI scans and are seen to be more repeatable than  $\text{MTR}_{\text{asym}}$ . This demonstration of z-spectrum fitting at 3.0 T and quantification of the repeatability of in vivo CEST metrics on a clinical scanner<sup>4,6,35</sup> is a necessary step towards the translation of CEST techniques to the clinic.

A study with a larger patient cohort is required to draw any conclusions about the magnitude of signal changes in disease and the work presented here may inform both the acquisition protocol and the powering of such a study.

Matlab scripts used in this analysis are available at: <https://github.com/vsefans/CEST>.

---

## Acknowledgment

Contract grant sponsor: Cancer Research UK (CRUK) and the Engineering and Physical Sciences Research Council (EPSRC) via the Comprehensive Cancer Imaging Centre (CCIC) which is a collaboration between University College London (UCL) and King's College London (KCL); Contract grant sponsor: National Institute for Health Research University College London Hospitals Biomedical Research Centre; Contract grant sponsor: European Union's Horizon 2020 Research and Innovation Programme; Contract grant number: 667510.

---

## References

1. Jones CK, Schlosser MJ, van Zijl PCM, Pomper MG, Golay X, Zhou J. Amide proton transfer imaging of human brain tumors at 3T. *Magn Reson Med* 2006;56:585–592.
2. Zhou J, et al. Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. *Magn Reson Med* 2008;60:842–849.
3. Zhang S, et al. CEST-Dixon for human breast lesion characterization at 3 T: A preliminary study. *Magn Reson Med* 2018;80:895–903.
4. Dula AN, et al. Amide proton transfer imaging of the breast at 3 T: Establishing reproducibility and possible feasibility assessing chemotherapy response. *Magn Reson Med* 2013;70:216–224.
5. Schmitt B, et al. A new contrast in MR mammography by means of Chemical Exchange Saturation Transfer (CEST) imaging at 3 Tesla: Preliminary results. *RöFo* 2011;183:1030–1036.

6. Yuan J, et al. Amide proton transfer-weighted imaging of the head and neck at 3T: A feasibility study on healthy human subjects and patients with head and neck cancer. *NMR Biomed* 2014;27:1239–1247.
7. Wang J, et al. SU-E-J-225: CEST imaging in head and neck cancer patients. *Med Phys* 2015;42:3317–3317.
8. Jia G, et al. Amide proton transfer MR imaging of prostate cancer: A preliminary study. *J Magn Reson Imaging* 2011;33:647–654.
9. Takayama Y, et al. Amide proton transfer (APT) magnetic resonance imaging of prostate cancer: Comparison with Gleason scores. *Magn Reson Mater Phys Biol Med* 2016;29:671–679.
10. Barentsz JO, et al. ESUR prostate MR guidelines 2012. *Eur Radiol* 2012;22:746–757.
11. Bomers JGR, Barentsz JO. Standardization of multiparametric prostate MR imaging using PI-RADS. *Biomed Res Int* 2014;2014:431680.
12. Ahmed HU, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study. *Lancet* 2017;389:815–822.
13. Harada T, et al. Five-point Likert scaling on MRI predicts clinically significant prostate carcinoma. *BMC Urol* 2015;15:91.
14. Kasivisvanathan V, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. *N Engl J Med* 2018;378:1767–1777.
15. Kelly RS, Vander Heiden MG, Giovannucci E, Mucci LA. Metabolomic biomarkers of prostate cancer: Prediction, diagnosis, progression, prognosis, and recurrence. *Cancer Epidemiol Biomarkers Prev* 2016;25:887–906.
16. Schuenke P, Windschuh J, Roeloffs V, Ladd ME, Bachert P, Zaiss M. Simultaneous mapping of water shift and B<sub>1</sub> (WASABI)—Application to field inhomogeneity correction of CESTMRI data. *Magn Reson Med* 2017;77:571–580.
17. Heo HY, et al. Whole-brain amide proton transfer (APT) and nuclear Overhauser enhancement (NOE) imaging in glioma patients using low-power steady-state pulsed chemical exchange saturation transfer (CEST) imaging at 7T. *J Magn Reson Imaging* 2016;44:41–50.
18. Kogan F, Hariharan H, Reddy R. Chemical Exchange Saturation Transfer (CEST) Imaging: Description of technique and potential clinical applications. *Curr Radiol Rep* 2013;22:102–114.
19. Jones CK, et al. Nuclear Overhauser enhancement (NOE) imaging in the human brain at 7T. *Neuroimage* 2013;77:114–124.
20. Zaiss M, Schmitt B, Bachert P. Quantitative separation of CEST effect from magnetization transfer and spillover effects by Lorentzian-line-fit analysis of z-spectra. *J Magn Reson* 2011;211:149–155.
21. Zaiss M, Bachert P. Chemical exchange saturation transfer (CEST) and MR Z<sup>-</sup>spectroscopy in vivo: A review of theoretical approaches and methods. *Phys Med Biol* 2013;58:R221–R269.
22. Desmond KL, Moosvi F, Stanisz GJ. Mapping of amide, amine, and aliphatic peaks in the CEST spectra of murine xenografts at 7 T. *Magn Reson Med* 2013;1853:1841–1853.
23. Cai K, et al. CEST signal at 2 ppm (CEST@2 ppm) from Z-spectral fitting correlates with creatine distribution in brain tumor. *NMR Biomed* 2015; 28:1–8.
24. Henkelman RM, Stanisz GJ, Graham SJ. Magnetization transfer in MRI: A review. *NMR Biomed* 2001;14:57–64.
25. Sled JG, Pike GB. Quantitative imaging of magnetization transfer exchange and relaxation properties in vivo using MRI. *Magn Reson Med* 2001;46:923–931.
26. Hua J, Jones CK, Blakeley J, Smith SA, van Zijl PCM, Zhou J. Quantitative description of the asymmetry in magnetization transfer effects around the water resonance in the human brain. *Magn Reson Med* 2007;58:786–793.
27. Ng MC, Hua J, Hu Y, Luk KD, Lam EY. Magnetization transfer (MT) asymmetry around the water resonance in human cervical spinal cord. *J Magn Reson Imaging* 2009;29:523–528.
28. van Zijl PCM, Lam WW, Xu J, Knutsson L, Stanisz GJ. Magnetization transfer contrast and chemical exchange saturation transfer MRI. Features and analysis of the field-dependent saturation spectrum. *Neuroimage* 2018;168:222–241.
29. de Bazelaire CMJ, Duhamel GD, Rofsky NM, Alsop DC. MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: Preliminary results. *Radiology* 2004;230:652–659.
30. Bland JM, Altman D. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1986;327: 307–310.
31. Fedorov A, Vangel MG, Tempany CM, Fennessy FM. Multiparametric magnetic resonance imaging of the prostate: Repeatability of volume and apparent diffusion coefficient quantification. *Invest Radiol* 2017;52: 538–546.
32. Arlinghaus LR, Dortch RD, Whisenant JG, Kang H, Abramson RG, Yankeelov TE. Quantitative magnetization transfer imaging of the breast at 3.0 T: Reproducibility in healthy volunteers. *Tomography* 2016;2:260–266.
33. Barrett T, et al. Diagnostic evaluation of magnetization transfer and diffusion kurtosis imaging for prostate cancer detection in a re-biopsy population. *Eur Radiol* 2018;28:3141–3150.
34. Weinreb JC, et al. Prostate cancer: Sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy—Results of ACRIN prospective multi-institutional clinicopathologic study. *Radiology* 2009;251:122–133.
35. Togao O, et al. Scan-rescan reproducibility of parallel transmission based amide proton transfer imaging of brain tumors. *J Magn Reson Imaging* 2015;42:1346–1353.
36. Wech T, Ostler HK. Robust motion correction in CEST imaging exploiting low-rank approximation of the z-spectrum. *Magn Reson Med* 2018; 80:1979–1988.
37. Zhou IY, Wang E, Cheung JS, Zhang X, Fulci G, Sun PZ. Quantitative chemical exchange saturation transfer (CEST) MRI of glioma using Image Downsampling Expedited Adaptive Least-squares (IDEAL) fitting. *Sci Rep* 2017;7:84.